Immune Design Corp. (IMDZ)


Stock Price Forecast

April 1, 2019


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Immune Design Corp. chart...

About the Company

Develops therapeutic vaccines for the treatment of infectious and malignant diseases

Please visit http://www.immunedesign.com for more information about the company.

Sector

Health Technology

Industry

Biotechnology

Employees

50

Exchange

NASDAQ

Website

http://www.immunedesign.com

$2M

Total Revenue

50

Employees

$281M

Market Capitalization

-5.13

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $IMDZ News

Daniel Janney's Net Worth

7d ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include IMMUNE DESIGN CORP., ZS Pharma, Inc., SUTRO BIOPHARMA, INC., TREVENA INC, APPLIED GENETIC TECHNOLOGIES CORP, aTYR PHARMA ...

AC Immune SA ACIU

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Immune Engineering

21d ago, source: Drexel University

Given the increasing understanding of the importance of the immune system in biomaterial design, drug delivery, and cell and gene therapy, students earning a minor in Immune Engineering will be well ...

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

9d ago, source: Wall Street Journal

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Kaspersky Thin Client 2.0: Cyber Immune protection with enhanced connectivity, performance and design

1d ago, source: Zawya

Kaspersky Thin Client 2.0 is available in the Middle East through a Memorandum of Understanding (MoU) with SCOPE Middle East ...

Q&A: When will patients see personalized cancer vaccines?

on MSN ago, source:

Catherine Wu has been a pioneer in a promising approach to fight cancer: vaccines that target specific immune-stimulating ...

SAB Biotherapeutics Provides SAB-142 Trial Update

3d ago, source:

SAB-142 is a human alternative to rabbit anti-thymocyte globulin (ATG). SAB-142’s mechanism of action is analogous to that of rabbit ATG, which has been clinically validated in multiple clinical ...

SHELT launches new business unit in Nigeria to provide cloud and cybersecurity services

1d ago, source: technext24

Leading provider of cybersecurity solutions, SHELT Global Limited has announced the launch of a new business unit in Nigeria.

How ORNL researchers aid in the discovery of new drugs

4d ago, source: The Oak Ridger on MSN

It is advised not to take it with commonly used drugs such as statins. “Proteins mutate, so the virus could develop drug ...

Could Some Auto-Immune Diseases Become a Thing of the Past?

1d ago, source: The Talbot Spy

The Invisible Kingdom is a book that chronicles Meghan O’Rourke’s struggle with an undiagnosed auto-immune disease. She ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...